Approved Neurology Deal Benchmarks

Approved neurology licensing deals carry a median total deal value of $7.1B, with upfront payments ranging from $1.6B to $2.7B. At this stage, deal structures are shifted toward higher upfront allocations, reflecting reduced regulatory risk and near-term commercial potential. The recommended split allocates 31% to upfront and 69% to milestones.

The neurology landscape at the approved stage is characterized by moderate competitive intensity with significant unmet need in neurodegenerative indications. Development milestones average $244M, regulatory milestones contribute $1.2B, and commercial milestones reach $3.4B. Disease-modifying therapies and novel CNS delivery platforms are attracting increasing licensee interest following breakthroughs in amyloid-targeted approaches.